Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge

Microbes and Infection

Volumn 12, Issue 12-13, 2010, Pages 967-977

  Chávez Fumagalli, Miguel A ^a   Costa, Mariana A F ^a   Oliveira, Dulcilene M ^a   Ramírez, Laura ^b   Costa, Lourena E ^a   Duarte, Mariana C ^a   Martins, Vivian T ^a   Oliveira, Jamil S ^a   Olortegi, Carlos C ^a   Bonay, Pedro ^b   Alonso, Carlos ^b   Tavares, Carlos A P ^a   Soto, Manuel ^b   Coelho, Eduardo A F ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

BALB c mice; Leishmania; Leishmania ribosomal proteins; Tegumentary leishmaniasis; Vaccine; Visceral leishmaniasis

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LEISHMANIA VACCINE; RIBOSOME PROTEIN; SAPONIN;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; IMMUNOGENICITY; LEISHMANIA CHAGASI; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; SPLEEN; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FOOT; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIASIS; LEISHMANIASIS VACCINES; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PROTOZOAN PROTEINS; RIBOSOMAL PROTEINS; SAPONINS;

LEISHMANIA AMAZONENSIS; LEISHMANIA DONOVANI CHAGASI; LEISHMANIA INFANTUM; MUS;

EID: 77958086444     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.06.008     Document Type: Article

References (50)

1. Barral A., Pedral-Sampaio D., Grimaldi G., Momen H., McMahon-Pratt D., Ribeiro de Jesus A., Almeida R., Badaro R., Barral-Netto M., Carvalho E.M., et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med. Hyg. 1991, 44:536-546.
2. Grimaldi G., Tesh R.B. Leishmaniasis of the new world: current concepts and implications for future research. Clin. Microbiol. Rev. 1993, 6:230-250.
3. Noben-Trauth N., Lira R., Nagase H., Paul W.E., Sacks D.L. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 2003, 170:5152-5158.
4. Gumy A., Louis J.A., Launois P. The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. Int. J. Parasitol. 2004, 34:433-444.
5. Iborra S., Parody N., Abanades D.R., Bonay P., Prates D., Novais F.O., Barral-Netto M., Alonso C., Soto M. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect. 2008, 10:1133-1141.
6. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008, 26:1709-1724.
7. Rosa R., Marques C., Rodrigues O.R., Santos-Gomes G.M. Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response. Vaccine 2007, 25:4525-4532.
8. Kubar J., Fragaki K. Recombinant DNA-derived Leishmania proteins: from the laboratory to the field. Lancet Infect. Dis. 2005, 5:107-114.
9. Coelho E.A., Ramirez L., Costa M.A., Coelho V.T., Martins V.T., Chavez-Fumagalli M.A., Oliveira D.M., Tavares C.A., Bonay P., Nieto C.G., Abanades D.R., Alonso C., Soto M. Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts. Clin. Vaccine Immunol. 2009, 16:1774-1780.
10. Sun H.X., Xie Y., Ye Y.P. Advances in saponin-based adjuvants. Vaccine 2009, 27:1787-1796.
11. Santos W.R., de Lima V.M., de Souza E.P., Bernardo R.R., Palatnik M., Palatnik de Sousa C.B. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 2002, 21:30-43.
12. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., de Oliveira Aguiar-Soares R.D., Coura-Vital W., de Abreu R.T., Malaquias L.C., Gontijo N.F., Brodskyn C., de Oliveira C.I., Costa D.J., de Lana M., Reis A.B. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 2008, 26:623-638.
13. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 1988, 56:3272-3279.
14. Fernandes A.P., Costa M.M., Coelho E.A., Michalick M.S., de Freitas E., Melo M.N., Luiz Tafuri W., Resende Dde M., Hermont V., Abrantes Cde F., Gazzinelli R.T. Protective immunity against challenge with Leishmania chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008, 26:5888-5895.
15. Coelho E.A., Tavares C.A., Carvalho F.A., Chaves K.F., Teixeira K.N., Rodrigues R.C., Charest H., Matlashewski G., Gazzinelli R.T., Fernandes A.P. Immune responses induced by the Leishmania donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania amazonensis infection. Infect. Immun. 2003, 71:3988-3994.
16. Afonso L.C., Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 1993, 61:2952-2959.
17. Awasthi A., Mathur R.K., Saha B. Immune response to Leishmania infection. Indian J. Med. Res. 2004, 119:238-258.
18. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 1998, 4:1409-1415.
19. Pereira B.A., Alves C.R. Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis. Vet. Parasitol. 2008, 158:239-255.
20. Garg R., Dube A. Animal models for vaccine studies for visceral leishmaniasis. Indian J. Med. Res. 2006, 123:439-454.
21. Requena J.M., Alonso C., Soto M. Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol. Today 2000, 16:246-250.
22. Soto M., Ramírez L., Pineda M., González V., Entringer P., Indiani de Oliveira C., Nascimento I., Souza A., Corvo L., Alonso C., Bonay P., Brodskyn C., Barral A., Barral-Netto M., Iborra S. Searching genes encoding Leishmania antigens for diagnosis and protection. Scho. Res. Exch. 2009, Article ID 173039.
23. Skeiky Y.A., Benson D.R., Elwasila M., Badaro R., Burns J.M., Reed S.G. Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins. Infect. Immun. 1994, 62:1643-1651.
24. Cordeiro-Da-Silva A., Borges M.C., Guilvard E., Ouaissi A. Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation. Infect. Immun. 2001, 69:6588-6596.
25. Roberts M.T., Stober C.B., McKenzie A.N., Blackwell J.M. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect. Immun. 2005, 73:7620-7628.
26. Stober C.B., Lange U.G., Roberts M.T., Gilmartin B., Francis R., Almeida R., Peacock C.S., McCann S., Blackwell J.M. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 2006, 24:2602-2616.
27. Coffman R.L. Mechanisms of helper T-cell regulation of B-cell activity. Ann. N.Y. Acad. Sci. 1993, 681:25-28.
28. Wilson M.E., Jeronimo S.M., Pearson R.D. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb. Pathog. 2005, 38:147-160.
29. Ramirez L., Iborra S., Cortes J., Bonay P., Alonso C., Barral-Netto M., Soto M. BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge. J. Biomed. Biotechnol. 2010, 2010:181690.
30. Park A.Y., Hondowicz B., Kopf M., Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J. Immunol. 2002, 168:5771-5777.
31. Bhowmick S., Ravindran R., Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect. Immun. 2008, 76:1003-1015.
32. Rachamim N., Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 1993, 150:2322-2331.
33. + cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect. Immun. 2007, 75:5956-5966.
34. Stager S., Smith D.F., Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 2000, 165:7064-7071.
35. Mary C., Auriault V., Faugere B., Dessein A.J. Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon- and interleukin-5-producing CD4(+) antigen-specific T cells. Infect. Immun. 1999, 67:5559-5566.
36. Stobie L., Gurunathan S., Prussin C., Sacks D.L., Glaichenhaus N., Wu C.Y., Seder R.A. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. USA 2000, 97:8427-8432.
37. Bhowmick S., Ravindran R., Ali N. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 2007, 25:6544-6556.
38. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 2005, 174:7160-7171.
39. Taylor A.P., Murray H.W. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J. Exp. Med. 1997, 185:1231-1239.
40. Murray H.W. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J. Infect. Dis. 1997, 175:1477-1479.
41. Zanin F.H., Coelho E.A., Tavares C.A., Marques-da-Silva E.A., Silva Costa M.M., Rezende S.A., Gazzinelli R.T., Fernandes A.P. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect. 2007, 9:1070-1077.
42. Kima P.E., Constant S.L., Hannum L., Colmenares M., Lee K.S., Haberman A.M., Shlomchik M.J., McMahon-Pratt D. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J. Exp. Med. 2000, 191:1063-1068.
43. Lima G.M., Puel A., Decreusefond C., Bouthillier Y., Mevel J.C., Abrahamsohn I.A., Mouton D. Susceptibility and resistance to Leishmania amazonensis in H-2q syngeneic high and low antibody responder mice (Biozzi mice). Scand. J. Immunol. 1998, 48:144-151.
44. Murphy M.L., Wille U., Villegas E.N., Hunter C.A., Farrell J.P. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 2001, 31:2848-2856.
45. Murray H.W., Lu C.M., Mauze S., Freeman S., Moreira A.L., Kaplan G., Coffman R.L. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 2002, 70:6284-6293.
46. Padigel U.M., Alexander J., Farrell J.P. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 2003, 171:3705-3710.
47. Dumas C., Muyombwe A., Roy G., Matte C., Ouellette M., Olivier M., Papadopoulou B. Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect. Immun. 2003, 71:6499-6509.
48. Murray H.W., Cervia J.S., Hariprashad J., Taylor A.P., Stoeckle M.Y., Hockman H. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J. Clin. Invest. 1995, 95:1183-1192.
49. Follador I., Araujo C., Orge G., Cheng L.H., de Carvalho L.P., Bacellar O., Almeida R.P., Carvalho E.M. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine 2002, 20:1365-1368.
50. Badaro R., Lobo I., Nakatani M., Muinos A., Netto E.M., Coler R.N., Reed S.G. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: a case report. Braz. J. Infect. Dis. 2001, 5:223-232.